Trade Genfit SA - GNFTfr CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.16 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.020029% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | -0.002193% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | EUR | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | France | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.31 |
| Open | 4.23 |
| 1-Year Change | 32.6% |
| Day's Range | 4.18 - 4.36 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | 4.18 | -0.06 | -1.42% | 4.24 | 4.37 | 4.16 |
| Nov 14, 2024 | 4.31 | -0.59 | -12.04% | 4.90 | 4.94 | 4.04 |
| Nov 13, 2024 | 4.83 | 0.07 | 1.47% | 4.76 | 4.85 | 4.70 |
| Nov 12, 2024 | 4.80 | -0.09 | -1.84% | 4.89 | 4.99 | 4.74 |
| Nov 11, 2024 | 4.87 | 0.08 | 1.67% | 4.79 | 5.01 | 4.74 |
| Nov 8, 2024 | 4.90 | -0.44 | -8.24% | 5.34 | 5.43 | 4.77 |
| Nov 7, 2024 | 5.36 | 0.01 | 0.19% | 5.35 | 5.36 | 5.16 |
| Nov 6, 2024 | 5.21 | -0.13 | -2.43% | 5.34 | 5.48 | 5.21 |
| Nov 5, 2024 | 5.36 | 0.02 | 0.37% | 5.34 | 5.59 | 5.29 |
| Nov 4, 2024 | 5.42 | 0.05 | 0.93% | 5.37 | 5.60 | 5.33 |
| Nov 1, 2024 | 5.37 | 0.24 | 4.68% | 5.13 | 5.40 | 5.10 |
| Oct 31, 2024 | 5.15 | -0.14 | -2.65% | 5.29 | 5.31 | 5.09 |
| Oct 30, 2024 | 5.32 | 0.18 | 3.50% | 5.14 | 5.50 | 5.14 |
| Oct 29, 2024 | 5.20 | 0.17 | 3.38% | 5.03 | 5.25 | 5.03 |
| Oct 28, 2024 | 5.04 | -0.07 | -1.37% | 5.11 | 5.21 | 4.99 |
| Oct 25, 2024 | 5.07 | 0.11 | 2.22% | 4.96 | 5.11 | 4.94 |
| Oct 24, 2024 | 5.03 | 0.00 | 0.00% | 5.03 | 5.16 | 4.92 |
| Oct 23, 2024 | 5.02 | -0.24 | -4.56% | 5.26 | 5.41 | 5.00 |
| Oct 22, 2024 | 5.28 | -0.08 | -1.49% | 5.36 | 5.42 | 5.19 |
| Oct 21, 2024 | 5.40 | 0.18 | 3.45% | 5.22 | 5.48 | 5.00 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Genfit Company profile
About Genfit SA
Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
Financial summary
BRIEF: For the six months ended 30 June 2021, Genfit SA revenues decreased 42% to EUR3.4M. Net income totaled EUR9.1M vs. loss of EUR53M. Revenues reflect Public Financing of research expenditure decrease of 38% to EUR3.2M, Other Operating Income decrease of 66% to EUR174K, Revenue decrease of 91% to EUR11K. Net Income reflects R&D Subcontractors decrease of 38% to EUR15M (expense).
Equity composition
01/2014, Rights Issue, 1 new share for every 33 shares held @ EUR6.98 (Factor: 1.00937).10/2016, Rights Issue, 1 new share for every 9 shares held @ EUR14.3 (Factor: 1.09242).
| Industry: | Biotechnology & Medical Research (NEC) |
Parc Eurasanté 885 avenue Eugène Avinée
LOOS
HAUTS-DE-FRANCE 59120
FR
News
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024
US elections: Trump leads the polls, but tariff talk spooks investors
As the US elections get closer we look at how Trump’s tariff plans could affect markets.
15:02, 22 October 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com